At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NRSN Neurosense Therapeutics Ltd
Market Closed 11-15 16:00:00 EST
1.23
-0.07
-5.38%
High1.28Low1.19Vol178.76K
Open1.28D1 Closing1.30Amplitude7.03%
Mkt Cap23.95MTradable Cap17.86MTotal Shares19.47M
T/O220.73KT/O Rate1.23%Tradable Shares14.52M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Neurosense Therapeutics Secures $30 Million Equity Deal
TIPRANKS  ·  11-01
Neurosense Therapeutics Secures $30 Million Equity Deal
NeuroSense Completes Key ALS Trial Phase
TIPRANKS  ·  10-30
NeuroSense Completes Key ALS Trial Phase
Neurosense, FDA to Meet Nov. 6 to Discuss Design of Amyotrophic Lateral Sclerosis Treatment Trial; Shares Rise
MT Newswires Live  ·  10-28
Neurosense, FDA to Meet Nov. 6 to Discuss Design of Amyotrophic Lateral Sclerosis Treatment Trial; Shares Rise
BRIEF-Neurosense Secures Key FDA Meeting To Advance Its Phase 3 ALS Trial And NDA Submission
Reuters  ·  10-28
BRIEF-Neurosense Secures Key FDA Meeting To Advance Its Phase 3 ALS Trial And NDA Submission
Neurosense: in Canada, Plans to Submit Dossier in Q2 2025, With Regulatory Decision on Commercialization Expected by Q1 2026
THOMSON REUTERS  ·  10-28
Neurosense: in Canada, Plans to Submit Dossier in Q2 2025, With Regulatory Decision on Commercialization Expected by Q1 2026
Neurosense Therapeutics: FDA Type C Meeting Scheduled for Nov 6 for Phase 3 ALS Trial
THOMSON REUTERS  ·  10-28
Neurosense Therapeutics: FDA Type C Meeting Scheduled for Nov 6 for Phase 3 ALS Trial
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
Benzinga  ·  10-28
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
NeuroSense’s PrimeC Shows Potential in ALS Treatment
TIPRANKS  ·  10-24
NeuroSense’s PrimeC Shows Potential in ALS Treatment
NeuroSense’s PrimeC shows microRNA improvement in ALS
TIPRANKS  ·  10-24
NeuroSense’s PrimeC shows microRNA improvement in ALS
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
PR Newswire  ·  10-24
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
NeuroSense Targets Key ALS Drug Market in Canada
TIPRANKS  ·  10-15
NeuroSense Targets Key ALS Drug Market in Canada
BRIEF-NeuroSense Advances Plans For Early Commercialization Of Groundbreaking ALS Treatment In Canada, Provides Further Updates
Reuters  ·  10-15
BRIEF-NeuroSense Advances Plans For Early Commercialization Of Groundbreaking ALS Treatment In Canada, Provides Further Updates
Neurosense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
THOMSON REUTERS  ·  10-15
Neurosense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
Neurosense Therapeutics Ltd: Dossier Submission Planned for Q2 2025; Regulatory Decision Expected by Q1 2026
THOMSON REUTERS  ·  10-15
Neurosense Therapeutics Ltd: Dossier Submission Planned for Q2 2025; Regulatory Decision Expected by Q1 2026
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
PR Newswire  ·  10-15
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
Maxim Group Keeps Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)
TIPRANKS  ·  10-12
Maxim Group Keeps Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)
NeuroSense Therapeutics Seeking Early Regulatory Approval for Prospective ALS Treatment in Canada
MT Newswires Live  ·  10-09
NeuroSense Therapeutics Seeking Early Regulatory Approval for Prospective ALS Treatment in Canada
NeuroSense Targets Early ALS Drug Approval in Canada
TIPRANKS  ·  10-09
NeuroSense Targets Early ALS Drug Approval in Canada
BRIEF-Neurosense Therapeutics Plans To File For Early Commercialization Of ALS Treatment In Canada
Reuters  ·  10-09
BRIEF-Neurosense Therapeutics Plans To File For Early Commercialization Of ALS Treatment In Canada
Neurosense Therapeutics: Plans to Seek Approval in Additional Countries
THOMSON REUTERS  ·  10-09
Neurosense Therapeutics: Plans to Seek Approval in Additional Countries

Introduction

Company Name.
Neurosense Therapeutics Ltd
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Issue price:
--